目的：用Meta分析的方法系统评价利妥昔单抗(rituximab)联合常规化疗治疗B细胞淋巴瘤的有效性和安全性。方法：计算机检索EMBASE、PUBMED、Cochrane图书馆、VIP、CNKI、CBM数据库，全面收集有关利妥昔单抗联合常规化疗治疗B细胞淋巴瘤的随机对照试验（randomized controlled trial, RCT）论文，两名评价者单独评价纳入研究的方法学质量并提取资料，用RevMan 5.0软件进行Meta分析。结果：共纳入10篇RCT文献，Meta分析结果显示，与常规化疗相比，利妥昔单抗联合常规化疗提高了B细胞淋巴瘤患者的总生存时间\[HR=0.64，95%CI（0.53，0.77）\]和总有效率\[RR=1.21，95%CI（1.11，132）\]。两组的不良反应在3/4级感染、3/4级血小板减少症方面差异无统计学意义，其相对危险度（95%CI）分别为1.15（0.58， 2.30）、1.04（0.71，1.52）；而在3/4级粒细胞减少症、3/4级白细胞减少症、3/4级发热方面差异有统计学意义，其相对危险度（95%CI）分别为1.16 (1.02，1.31） 、1.31（1.12，1.53）、3.49（1.56，7.78）。结论：利妥昔单抗联合常规化疗可以显著提高B细胞淋巴瘤患者的总生存时间和总有效率，但3/4级粒细胞减少症、3/4级白细胞减少症、3/4级发热的发生率较高

Objective:To systematically assess the efficacy and safety of rituximab combined with routine chemotherapy in the treatment of B-cell lymphoma by Meta-analysis. Methods: We searched Embase, Pubmed, the Cochrane Library, VIP, CNKI, and CBM literature databases for randomized controlled trials (RCTs) of rituximab combined with routine chemotherapy in the treatment of B-cell lymphoma. Two reviewers independently assessed the quality of the included studies and extracted the data. The data were analyzed by Review Manager software (version 5.0). Results: Ten RCTs were finally included in the present analysis, and the results showed that rituximab combined with routine chemotherapy improved the overall survival rate (HR=0.64, 95% CI \[0.53, 0.77\]) and overall response rate (RR=1.21, 95% CI \[1.11, 1.32\]) of B-cell lymphoma patients compared with routine chemotherapy. There was no statistical difference between the two groups in 3/4 grade infection, 3/4 grade thrombocytopenia, with the relative risk being 1.15 (0.58, 230) and 1.04 (0.71, 1.52), respectively. There was significant difference in 3/4 grade granulocytopenia, 3/4 grade granulocytopenia, 3/4 grade leukocytopenia, and 3/4 grade fever, with the relative risk being 1.16 (1.02, 1.31), 1.31 (112, 153) and 349 (1.56, 778), respectively. Conclusion: Rituximab combined with routine chemotherapy can improve the overall survival rate and overall response rate of B-cell lymphoma patients, but results in a higher incidence of 3/4 grade granulocytopenia, 3/4 grade granulocytopenia, 3/4 grade leukocytopenia, and 3/4 grade fever.